DaVita (DVA)

NYSE Health Care Health Care Services S&P 500
$191.35
-3.47 (-1.78%)
Close of Nov 06, 2026 · end-of-day data
SMA 50SMA 2005Y/10Y use weekly candles (10/40-week averages)

Performance

price return
1W+2.0%
1M+8.1%
3M+4.2%
6M-3.7%
YTD+68.4%
1Y+57.9%
3Y+147.1%
5Y+85.3%

Key statistics

Full financials →
Market cap$12.0B
P/E (TTM)14.2
EPS (TTM, diluted)$13.51
P/S0.85
P/B—
EV / EBITDA7.9
Revenue (TTM)$14.17B
Revenue growth+6.4%
Net margin6.5%
ROE—
Debt / equity—
FCF yield10.7%
Dividend yield—
Payout ratio—
Beta (1Y)-0.06
Volatility (1Y)45.3%
52-week range$101.00 – $247.49
Avg volume (50D)734.81K

Revenue & net income — last 8 quarters

Statements →
Oct 29, 4:06 PM ET

DaVita Reports Third Quarter 2026 Results and Updates Full-Year Outlook

Mixed earnings 2.02

DaVita Inc. announced consolidated revenues of $3.578 billion and diluted earnings per share of $3.40 for the third quarter ended September 30, 2026. The company also updated its full-year 2026 guidance ranges for adjusted operating income and adjusted diluted earnings per share.

  • Consolidated revenues for Q3 2026 were $3.578 billion with an operating income of $499 million.
  • Diluted earnings per share was $3.40 and adjusted diluted earnings per share was $3.82 for the quarter ended September 30, 2026.
  • The company repurchased 0.6 million shares for $111 million during the third quarter of 2026 at an average price of $186.21 per share.
  • Updated 2026 guidance projects adjusted operating income between $2.175 billion and $2.250 billion.
Read the filing on SEC.gov ↗
Aug 4, 4:08 PM ET

DaVita Q2 2026 revenue rises to $3.554 billion; diluted EPS $4.02

Positive earnings Written later 2.02

DaVita reported results for the quarter ended June 30, 2026, with total revenues of $3.554 billion, up from $3.380 billion a year earlier, and diluted earnings per share of $4.02, up from $2.58. Operating income rose to $579 million from $538 million, and the company reaffirmed its 2026 guidance ranges for adjusted operating income, adjusted diluted EPS, and free cash flow. The results show gains in revenue, operating income, and per-share profit for shareholders.

  • Total revenues were $3.554 billion, compared with $3.380 billion in the second quarter of 2025.
  • Diluted EPS was $4.02, compared with $2.58 a year earlier; operating income was $579 million, a 16.3% margin.
  • Current 2026 guidance: adjusted operating income of $2,150 million to $2,250 million and adjusted diluted EPS of $14.10 to $15.20.
  • During the quarter the company repurchased 2.2 million shares for $348 million and added a $500 million Term Loan B-2 tranche.
Read the filing on SEC.gov ↗
Jun 8, 4:33 PM ET

DaVita adds $500 million term loan under Ninth Amendment to credit agreement

Neutral financing Written later 1.012.035.07

DaVita entered a Ninth Amendment to its credit agreement on June 8, 2026, providing a $500 million incremental term loan due May 2031. The company says it has used or will use the proceeds to repay part of its senior secured revolving loan, pay fees and expenses, and for general corporate purposes. At its June 4, 2026 annual meeting, stockholders elected all nine director nominees, ratified KPMG LLP as auditor, and approved executive compensation on an advisory basis.

  • $500 million incremental Tranche B-2 term loan, maturing May 2031, denominated in U.S. dollars
  • Interest at Term SOFR plus 175 basis points, or Base Rate plus 75 basis points, at the company's option
  • Proceeds to repay part of the senior secured revolving loan maturing November 2030, plus fees and general corporate purposes
  • Annual meeting on June 4, 2026: nine directors elected, KPMG LLP ratified, and say-on-pay approved; about 91% of shares represented
Read the filing on SEC.gov ↗
May 5, 4:09 PM ET

DaVita Q1 2026 diluted EPS rose to $2.87; 2026 adjusted EPS guidance raised

Positive guidance Written later 2.02

DaVita reported first-quarter 2026 revenue of $3.416 billion, up from $3.224 billion a year earlier, and operating income of $482 million, up from $439 million. It also raised its 2026 adjusted diluted EPS guidance to $14.10 to $15.20 from $13.60 to $15.00, which matters to shareholders because it signals higher expected profit for the year. Compared with the fourth quarter of 2025, revenue and operating income were lower.

  • Q1 2026 diluted EPS from continuing operations was $2.87, versus $2.00 in Q1 2025 and $2.94 in Q4 2025.
  • 2026 adjusted operating income guidance rose to $2,150 million to $2,250 million from $2,085 million to $2,235 million.
  • Free cash flow guidance for 2026 was unchanged at $1,000 million to $1,250 million.
  • The company repurchased 3.0 million shares for $403 million in Q1 2026 and 2.0 million more shares for $302 million from April 1 through May 5, 2026.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Recent SEC filings

EDGAR ↗

Famous investors who own DVA

All investors →
InvestorValue% of portfolioLast quarter
Warren Buffett Berkshire Hathaway $6.43B2.15% Reduced
Ray Dalio Bridgewater Associates $2.45M0.01% Reduced
Renaissance Technologies $1.42M0.00% Reduced

From each investor's latest 13F filing (Q2 2026); positions are as of the quarter end and filed up to 45 days later.

Trades disclosed by members of Congress

All DVA congressional trades →
TradedMemberTypeAmount
Sep 23, 2025Julie Johnson TX-32Buy$1,001 – $15,000
Sep 23, 2025Julie Johnson TX-32Sell$1,001 – $15,000
Sep 25, 2025Julie Johnson TX-32Sell$1,001 – $15,000

From House periodic transaction reports (STOCK Act); amounts are the form's ranges.

Insider transactions

All insider trades →
DateInsiderTypeSharesPriceValue
Oct 27Berkshire Hathaway Inc
10% Owner
Sell382.56K$180.43$69.03M
Sep 22Maughan David Paul
Chief Operating Officer, DKC
Tax Withholding7.50K$182.34$1.37M

Prices are end-of-day and split-adjusted. Financial data from DaVita's SEC XBRL filings. Not investment advice.